FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Antibody against human macrophage colony-stimulating factor 1 receptor (CSF-1R) is presented. Invention also relates to method of producing above antibody, pharmaceutical composition and use of above antibody.
EFFECT: invention enables inhibiting binding of CSF-1 with CSF-1R and can be used for treating cancer, bone loss, inflammatory diseases, as well as for preventing or treating metastases.
12 cl, 1 dwg, 7 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES PRIMARILY BINDING TO EXTRACELLULAR DOMAIN 4 OF HUMAN CSF-1R, AND USING THEM | 2010 |
|
RU2565541C2 |
| ANTIBODIES TO HUMAN CSF-1R AND USE THEREOF | 2011 |
|
RU2617966C2 |
| BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2014 |
|
RU2640253C2 |
| BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2009 |
|
RU2542382C2 |
| MACROPHAGE ACTIVATION MODULATION | 2012 |
|
RU2639553C2 |
| ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | 2012 |
|
RU2658603C2 |
| ANTIBODIES AGAINST HUMAN ANGIOPOIETIN-2 | 2009 |
|
RU2569107C2 |
| INTERLEUKIN (IL-17) ANTIBODY ANTAGONISTS FOR CANCER TREATMENT | 2007 |
|
RU2430110C2 |
| COMPOSITION COMPRISING TWO ANTIBODIES ENGINEERED TO HAVE REDUCED AND INCREASED EFFECTOR FUNCTION | 2013 |
|
RU2650788C2 |
| CELL DAMAGE INDUCING THERAPEUTIC MEDICINAL PRODUCT FOR ANTICANCER THERAPY | 2017 |
|
RU2746754C2 |
